December 5, 2017 02:35 PM EST
Pharma

In a blow to Eli Lil­ly, No­vo Nordisk lands FDA OK for their next big en­try in the di­a­betes mar­ket: Ozem­pic

John Carroll

Editor & Founder

An en­er­gized FDA has come through with an ap­proval of No­vo Nordisk’s once-week­ly GLP-1 di­a­betes drug semaglu­tide, open­ing the door to a mar­ket many an­a­lysts …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times